Syntara Limited · ASX:SNT
Syntara — Corporate Update (July 2026)
12 slides from Syntara's corporate update, Jul 28, 2026
Slide 1: June Quarterly Shareholder Update
For personal use only ™ June Quarterly Shareholder Update Gary Phillips, CEO
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the d
Slide 3: June Quarter 2026 - Highlights
June Quarter 2026 - Highlights For personal use only • Positive US FDA feedback supports the proposed clinical development pathway via Phase 2b trial of amsulostat in myelofibrosis • $8.0 million institutional placement strengthens balance sheet and extends expected cash runway into FY28 • Subsequen
Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 23 July 2026 $0.024 Close For personal use only Market cap A$47m 0.07 0.06 Cash balance (30 Jun 2026) A$13.5m 0.05 0.04 Enterprise value A$33.5m 0.03 0.02 0.01 Institutional Ownership 30 Jun 26 0 D&A Income
Slide 5: Three Assets Create Multiple Paths to Value
THREE ASSETS CREATE MULTIPLE PATHS TO VALUE A diversified clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease ASSET INDICATION TOTAL ADDRESSABLE MARKET DEVELOPMENT STATUS For personal use only • Phase 2a clinical proof of concept in MF - complete Haematological Myelo
Slide 6: Summary and Next Steps
SUMMARY AND NEXT STEPS Top-line Phase 2a data highlights amsulostat’s potential in MF Improvements of 50% or Meaningful spleen Of the 7 patients Differentiated TPP For personal use only more in total symptom volume reductions that completed 52 score (TSS50) (SVR) were observed weeks of treatment • C
Slide 7: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / / For personal use only DATE OF JULY-2026 APRIL-2026 MARCH-2026 DEC-2024 FEB-2024 ANNOUNCEMENT* Drug Name Navtemadlin AJ1-11095 Rovadicitinib Elritercept Pelabresib MDS and MF Myelofibrosis Lead Indication / Myelofibrosis Myelofi
Slide 8: Amsulostat: A New Future in MF Treatment Options
AMSULOSTAT: A NEW FUTURE IN MF TREATMENT OPTIONS Aspirational lifecycle development in MF enabled by first in class pan-LOX mechanism Ideal add-on for patients with Potentially best positioned Opportunity to slow For personal use only sub-optimal response to JAKi in frontline combination progression
Slide 9: Reduction in Inflammation
REDUCTION IN Binding Potential (BPND) P-value INFLAMMATION Putamen Mean at Mean at Mean change (Paired t- test) baseline 12 weeks For personal use only Statistically significant Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 reduction in brain inflammation observed unilaterally in the Left -0.001209
Slide 10: Innovative Trial Design to Evaluate Commercial Viability
INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026 For personal use only Healthy Volunteer Phase 1a Single Ascending Dose Trial design optimised for ✓ Dose-dependent target engagement confirmed inclusion criter
Slide 11: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS PARTICIPANTS For personal use only FDA approved development plan Myelofibrosis Trial Progression and partner engagement Interim safety and High Ri
Slide 12: For personal use only
For personal use only Gary Phillips Chief Executive Officer gary.phillips@syntaratx.com.au Alison Findlay Head Business Development & Licensing alison.findlay@syntaratx.com.au http://syntaratx.com.au